Open Payments analysis for ADHD stimulants: industry made 591,907 payments worth $20.1 million over 2014-2018, almost entirely meals, with pediatricians receiving 40.4% of payments — evidence of marketing contact, not of prescription quotas.
From January 1, 2014, to December 31, 2018, pharmaceutical companies made 591,907 payments totaling $20,101,250 to physicians for stimulants; 97.7% were for food and beverage.
JAMA Pediatr 2020;174(4):398-402 (PMC full text)
Open Payments analysis for ADHD stimulants: industry made 591,907 payments worth $20.1 million over 2014-2018, almost entirely meals, with pediatricians receiving 40.4% of payments — evidence of marketing contact, not of prescription quotas. Primary record of ADHD-drug marketing payments. No primary record of insurer or employer incentives tied to ADHD/psychiatric prescription quotas was found: NOT FOUND.